D
Celldex Therapeutics, Inc.
CLDX
$15.94
-$0.47-2.86%
D
Sell
4/8/2025Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 4/8/2025 due to an increase in the volatility index and valuation index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 4/8/2025 due to an increase in the volatility index and valuation index.
E
Sell
3/24/2025Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 3/24/2025 due to a decline in the volatility index and total return index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 3/24/2025 due to a decline in the volatility index and total return index.
D
Sell
3/3/2025Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 3/3/2025 due to an increase in the volatility index and total return index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 3/3/2025 due to an increase in the volatility index and total return index.
E
Sell
2/28/2025Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 2/28/2025 due to a significant decline in the total return index and volatility index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 2/28/2025 due to a significant decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 19.87 to 16.41, and EBIT declined 0.68% from -$27.7M to -$27.89M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 19.87 to 16.41, and EBIT declined 0.68% from -$27.7M to -$27.89M.
D
Sell
2/23/2023Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and solvency index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and solvency index.
D
Sell
5/31/2022Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index and volatility index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/31/2022 due to an increase in the valuation index and volatility index.
D
Sell
5/13/2022Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 68.93% from -$14.52M to -$24.53M, total revenue declined 47.9% from $334 to $174, and EBIT declined 15.58% from -$20.59M to -$23.79M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 68.93% from -$14.52M to -$24.53M, total revenue declined 47.9% from $334 to $174, and EBIT declined 15.58% from -$20.59M to -$23.79M.
D
Sell
5/5/2022Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
D
Sell
4/20/2022Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
3/21/2022Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 3/21/2022 due to a decline in the solvency index, valuation index and volatility index. The quick ratio declined from 29.86 to 24.71.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 3/21/2022 due to a decline in the solvency index, valuation index and volatility index. The quick ratio declined from 29.86 to 24.71.
D
Sell
1/21/2022Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 1/21/2022 due to an increase in the valuation index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 1/21/2022 due to an increase in the valuation index.
D
Sell
11/10/2021Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 11/10/2021 due to an increase in the solvency index and valuation index. The quick ratio increased from 11.36 to 29.86, and debt to equity declined from 0.01 to 0.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 11/10/2021 due to an increase in the solvency index and valuation index. The quick ratio increased from 11.36 to 29.86, and debt to equity declined from 0.01 to 0.
D
Sell
11/8/2021Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 62.45% from $546 to $887, earnings per share increased from -$0.7468 to -$0.6354, and EBIT increased 9.22% from -$13.96M to -$12.67M.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 62.45% from $546 to $887, earnings per share increased from -$0.7468 to -$0.6354, and EBIT increased 9.22% from -$13.96M to -$12.67M.
D
Sell
2/12/2020Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index.
E
Sell
1/6/2020Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 1/6/2020 due to a noticeable decline in the growth index, volatility index and valuation index. Total revenue declined 23.64% from $715 to $546, EBIT declined 5.15% from -$13.27M to -$13.96M, and operating cash flow declined 0.89% from -$11.04M to -$11.14M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 1/6/2020 due to a noticeable decline in the growth index, volatility index and valuation index. Total revenue declined 23.64% from $715 to $546, EBIT declined 5.15% from -$13.27M to -$13.96M, and operating cash flow declined 0.89% from -$11.04M to -$11.14M.
D
Sell
2/1/2019Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 2/1/2019 due to a major increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.1113 to -$0.0443, EBIT increased 36.93% from -$23.31M to -$14.7M, and operating cash flow increased 17.29% from -$17.4M to -$14.39M.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D- from E+ on 2/1/2019 due to a major increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.1113 to -$0.0443, EBIT increased 36.93% from -$23.31M to -$14.7M, and operating cash flow increased 17.29% from -$17.4M to -$14.39M.
E
Sell
5/11/2018Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 5/11/2018 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 2,975.55% from -$3.84M to -$118.13M, earnings per share declined from -$0.0281 to -$0.8405, and operating cash flow declined 43.55% from -$19.52M to -$28.02M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to E+ from D- on 5/11/2018 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 2,975.55% from -$3.84M to -$118.13M, earnings per share declined from -$0.0281 to -$0.8405, and operating cash flow declined 43.55% from -$19.52M to -$28.02M.
D
Sell
4/23/2018Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/23/2018 due to a decline in the volatility index and total return index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/23/2018 due to a decline in the volatility index and total return index.
D
Sell
3/12/2018Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 3/12/2018 due to a significant increase in the growth index and efficiency index. Earnings per share increased from -$0.2034 to -$0.0281, net income increased 85.43% from -$26.36M to -$3.84M, and operating cash flow increased 19.87% from -$24.36M to -$19.52M.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D from D- on 3/12/2018 due to a significant increase in the growth index and efficiency index. Earnings per share increased from -$0.2034 to -$0.0281, net income increased 85.43% from -$26.36M to -$3.84M, and operating cash flow increased 19.87% from -$24.36M to -$19.52M.
D
Sell
4/1/2016Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/1/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 8.95% from $318.63M to $290.11M, and net income declined 2.2% from -$31.98M to -$32.68M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D- from D on 4/1/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 8.95% from $318.63M to $290.11M, and net income declined 2.2% from -$31.98M to -$32.68M.
D
Sell
11/6/2015Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 11/6/2015 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 7.88% from $345.88M to $318.63M, and net income declined 1.17% from -$32.36M to -$31.98M.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 11/6/2015 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 7.88% from $345.88M to $318.63M, and net income declined 1.17% from -$32.36M to -$31.98M.
D
Sell
5/1/2015Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 5/1/2015 due to a substantial increase in the volatility index, total return index and growth index. Operating cash flow increased 46.7% from -$22.21M to -$32.59M, and EBIT increased 4.84% from -$29.55M to -$30.98M.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 5/1/2015 due to a substantial increase in the volatility index, total return index and growth index. Operating cash flow increased 46.7% from -$22.21M to -$32.59M, and EBIT increased 4.84% from -$29.55M to -$30.98M.
D
Sell
7/31/2014Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 7/31/2014 due to a decline in the total return index.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 7/31/2014 due to a decline in the total return index.
D
Sell
7/16/2014Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 7/16/2014 due to an increase in the valuation index.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 7/16/2014 due to an increase in the valuation index.
D
Sell
6/12/2014Downgrade
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 6/12/2014 due to a major decline in the volatility index, growth index and solvency index. Total revenue declined 32.9% from $620 to $416, and the quick ratio declined from 14.91 to 14.07.
Celldex Therapeutics, Inc. (CLDX) was downgraded to D from D+ on 6/12/2014 due to a major decline in the volatility index, growth index and solvency index. Total revenue declined 32.9% from $620 to $416, and the quick ratio declined from 14.91 to 14.07.
D
Sell
3/7/2014Upgraded
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 3/7/2014 due to a major increase in the volatility index, solvency index and efficiency index. Total capital increased 104.02% from $156.75M to $319.8M, and the quick ratio increased from 8.19 to 14.91.
Celldex Therapeutics, Inc. (CLDX) was upgraded to D+ from D on 3/7/2014 due to a major increase in the volatility index, solvency index and efficiency index. Total capital increased 104.02% from $156.75M to $319.8M, and the quick ratio increased from 8.19 to 14.91.
NASDAQ
04/10/2025 4:00PM Eastern
Quotes delayed
